12:00 AM
 | 
Mar 29, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Onconase: Phase II data; Phase III

Data from 105 patients in a Phase II trial showed that 39 percent of patients had either tumor reduction or stabilization (clinical activity). Median...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >